Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pacira BioSciences Reports Sustained Pain Relief in Osteoarthritis with Gene Therapy Candidate PCRX-201 in Upcoming ACR Presentation

Pacira BioSciences reports positive data on gene therapy PCRX-201 for knee osteoarthritis, showing sustained pain relief for 104 weeks.Quiver AI SummaryPacira BioSciences, Inc. recently revealed promising...

PCRX : 17.52 (+2.88%)
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

PCRX : 17.52 (+2.88%)
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

PCRX : 17.52 (+2.88%)
Pacira: Q3 Earnings Snapshot

Pacira: Q3 Earnings Snapshot

PCRX : 17.52 (+2.88%)
Pacira BioSciences Reports Third Quarter 2024 Financial Results

PCRX : 17.52 (+2.88%)
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

PCRX : 17.52 (+2.88%)
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

PCRX : 17.52 (+2.88%)
Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock?

Investors in Pacira BioSciences, Inc. PCRX need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $25.00 Call had some of the highest implied...

PCRX : 17.52 (+2.88%)
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

PCRX : 17.52 (+2.88%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

PCRX : 17.52 (+2.88%)

Barchart Exclusives

ELF’s Unusual Options Activity Is a Thing of Questionable Beauty
E.L.F. Beauty’s options volume on Wednesday was 7x the 30-day average. The affordable makeup and skincare company’s unusual options activity stood out as one investor questioned its revenues. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar